A phase II study of BAY 43-9006 (NSC724772; CTEP-IND69,896) in patients with hormone refractory prostate cancer.
Phase of Trial: Phase II
Latest Information Update: 28 Mar 2016
At a glance
- Drugs Sorafenib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 21 Sep 2013 Additional lead trial centre added as reported by ClinicalTrials.gov.
- 18 Jan 2011 Actual end date (Jan 2011) added as reported by ClinicalTrials.gov.